

S1 Table. Characteristics of all randomized patients (intention-to-treat set)

| Variables | Total (n=111) | Combination therapy (group A, n=56) | Monotherapy (group B, n=55) | p-value |
|--|------------------|--|--------------------------------|----------------------|
| Age (yr) | | | | |
| < 75 | 46 (41.4) | 23 (41.1) | 23 (41.8) | 0.936 ^{a)} |
| ≥ 75 | 65 (58.6) | 33 (58.9) | 32 (58.2) | |
| Sex | | | | |
| Male | 83 (74.8) | 41 (73.2) | 42 (76.4) | 0.702 ^{a)} |
| Female | 28 (25.2) | 15 (26.8) | 13 (23.6) | |
| ECOG performance status ^{c)} | | | | |
| 0-1 | 88 (80.0) | 45 (81.8) | 43 (78.2) | 0.634 ^{a)} |
| 2 | 22 (20.0) | 10 (18.2) | 12 (21.8) | |
| Fluoropyrimidine backbone ^{d)} | | | | |
| 5-FU | 40 (38.1) | 21 (39.6) | 19 (36.5) | 0.942 ^{a)} |
| Capecitabine | 35 (33.3) | 17 (32.1) | 18 (34.6) | |
| S-1 | 30 (28.6) | 15 (28.3) | 15 (28.8) | |
| Lauren classification | | | | |
| Intestinal | 33 (29.7) | 20 (35.7) | 13 (25.0) | 0.143 ^{b)} |
| Diffuse | 25 (22.5) | 9 (16.1) | 16 (29.1) | |
| Mixed | 2 (1.8) | 2 (3.6) | 0 | |
| Unknown | 51 (45.9) | 25 (44.6) | 26 (47.3) | |
| Gastrectomy ^{c)} | | | | |
| Primary metastatic without gastrectomy | 78 (70.9) | 36 (65.5) | 42 (76.4) | 0.441 ^{a)} |
| Primary metastatic with gastrectomy | 14 (12.7) | 8 (14.5) | 6 (10.9) | |
| Recurrent | 18 (16.4) | 11 (20.0) | 7 (12.7) | |
| Previous adjuvant chemotherapy ^{e)} | | | | |
| No | 100 (92.6) | 49 (90.7) | 51 (94.4) | 0.716 ^{b)} |
| Yes | 8 (7.4) | 5 (9.3) | 3 (5.6) | |
| No. of metastatic organs | | | | |
| 0-1 | 67 (60.4) | 36 (64.3) | 31 (56.4) | 0.258 ^{a)} |
| 2 | 27 (24.3) | 10 (17.9) | 17 (30.9) | |
| 3 or more | 17 (15.3) | 10 (17.9) | 7 (12.7) | |
| Metastatic organs | | | | |
| Distant abdominal lymph nodes | 45 (40.5) | 23 (41.1) | 22 (40.0) | > 0.99 ^{b)} |
| Peritoneum | 40 (36.0) | 16 (28.6) | 24 (43.6) | 0.116 ^{b)} |
| Liver | 35 (31.5) | 19 (33.9) | 16 (29.1) | 0.684 ^{b)} |
| Lung | 14 (12.6) | 9 (16.1) | 5 (9.1) | 0.392 ^{b)} |
| Bone | 7 (6.3) | 4 (7.1) | 3 (5.5) | > 0.99 ^{b)} |
| Neck and mediastinal lymph nodes | 6 (5.4) | 2 (3.6) | 4 (7.3) | 0.438 ^{b)} |
| Others | 24 (21.6) | 12 (21.4) | 12 (21.8) | > 0.99 ^{b)} |

Values are presented as number (%). 5-FU, 5-fluorouracil; ECOG, Eastern Cooperative Oncology

Group. ^{a)}Chi-square test, ^{b)}Fisher's exact test, ^{c)}Data in one patient was missing, ^{d)}Six patients did not receive study treatment ^{e)}Data in three patients were missing.